Verrica Pharmaceuticals Inc.
VRCA
$0.4934
-$0.0595-10.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 344.00K | -1.78M | 5.18M | 3.83M | 1.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 344.00K | -1.78M | 5.18M | 3.83M | 1.99M |
| Cost of Revenue | 12.47M | 435.00K | 3.86M | 6.09M | 20.57M |
| Gross Profit | -12.12M | -2.22M | 1.32M | -2.26M | -18.58M |
| SG&A Expenses | 9.88M | 16.08M | 16.52M | 16.34M | 17.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.67M | 18.92M | 20.38M | 22.43M | 22.59M |
| Operating Income | -11.33M | -20.70M | -15.21M | -18.60M | -20.60M |
| Income Before Tax | -16.20M | -22.86M | -17.19M | -20.33M | -24.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.20M | -22.86M | -17.19M | -20.33M | -24.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.20M | -22.86M | -17.19M | -20.33M | -24.61M |
| EBIT | -11.33M | -20.70M | -15.21M | -18.60M | -20.60M |
| EBITDA | -11.14M | -20.46M | -14.95M | -18.34M | -20.45M |
| EPS Basic | -0.24 | -0.49 | -0.37 | -0.44 | -0.53 |
| Normalized Basic EPS | -0.15 | -0.31 | -0.23 | -0.27 | -0.30 |
| EPS Diluted | -0.24 | -0.49 | -0.37 | -0.44 | -0.53 |
| Normalized Diluted EPS | -0.15 | -0.31 | -0.23 | -0.27 | -0.30 |
| Average Basic Shares Outstanding | 67.33M | 46.81M | 46.50M | 46.48M | 46.31M |
| Average Diluted Shares Outstanding | 67.33M | 46.81M | 46.50M | 46.48M | 46.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |